Literature DB >> 16510145

Effects of MdmX on Mdm2-mediated downregulation of pRB.

Chiharu Uchida1, Seiichi Miwa, Tomoyasu Isobe, Kyoko Kitagawa, Takayuki Hattori, Toshiaki Oda, Hideyo Yasuda, Masatoshi Kitagawa.   

Abstract

Mdm2, a RING-finger type ubiquitin ligase, is overexpressed in a variety of human cancers. It promotes ubiquitination of the tumor suppressor p53 and can function as an oncogene by largely downregulating p53. Recently, we reported that Mdm2 degrades retinoblastoma tumor suppressor protein (pRB) via the ubiquitin-proteasome system. In the present study, we assessed the effects of MdmX, a structural homolog of Mdm2, on the Mdm2-mediated ubiquitination of pRB. MdmX is known to negatively regulate p53 function by enhancing the Mdm2-mediated ubiquitination and degradation of p53. Interestingly, MdmX inhibited the Mdm2-mediated pRB ubiquitination. Furthermore, an MdmX siRNA decreased the endogenous pRB level, while MdmX overexpression stimulated pRB functions in cultured cells. Therefore, MdmX may have different roles in the regulation of Mdm2 activity for ubiquitination of pRB and p53.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510145     DOI: 10.1016/j.febslet.2006.02.029

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Lysine-independent turnover of cyclin G1 can be stabilized by B'alpha subunits of protein phosphatase 2A.

Authors:  Hongyun Li; Koji Okamoto; Melissa J Peart; Carol Prives
Journal:  Mol Cell Biol       Date:  2008-11-03       Impact factor: 4.272

2.  Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis.

Authors:  Yiwei Zhang; Xin Zhang; Hua Lu
Journal:  Dev Biol       Date:  2014-09-28       Impact factor: 3.582

3.  MDMX under stress: the MDMX-MDM2 complex as stress signals hub.

Authors:  Anna de Polo; Varunika Vivekanandan; John B Little; Zhi-Min Yuan
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

4.  MDMX exerts its oncogenic activity via suppression of retinoblastoma protein.

Authors:  H Zhang; L Hu; W Qiu; T Deng; Y Zhang; J Bergholz; Z-X Xiao
Journal:  Oncogene       Date:  2015-02-23       Impact factor: 9.867

Review 5.  MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.

Authors:  Jin Wu; Guanting Lu; Xinjiang Wang
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 6.  Post-translational modifications on the retinoblastoma protein.

Authors:  Linbin Zhou; Danny Siu-Chun Ng; Jason C Yam; Li Jia Chen; Clement C Tham; Chi Pui Pang; Wai Kit Chu
Journal:  J Biomed Sci       Date:  2022-06-01       Impact factor: 12.771

Review 7.  MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.

Authors:  Jean-Christophe Marine; Aart G Jochemsen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

8.  Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy.

Authors:  Hiroshi Okamoto; Fumiyoshi Fujishima; Takashi Kamei; Yasuhiro Nakamura; Yohei Ozawa; Go Miyata; Toru Nakano; Kazunori Katsura; Shigeo Abe; Yusuke Taniyama; Tadashi Sakurai; Jin Teshima; Makoto Hikage; Hironobu Sasano; Noriaki Ohuchi
Journal:  BMC Cancer       Date:  2015-03-31       Impact factor: 4.430

Review 9.  Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB.

Authors:  Jesús Hernández-Monge; Adriana Berenice Rousset-Roman; Ixaura Medina-Medina; Vanesa Olivares-Illana
Journal:  Genes Cancer       Date:  2016-09

10.  MDM4 (MDMX) and its Transcript Variants.

Authors:  F Mancini; G Di Conza; F Moretti
Journal:  Curr Genomics       Date:  2009-03       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.